These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Russo AT; Berhanu A; Bigger CB; Prigge J; Silvera PM; Grosenbach DW; Hruby D Vaccine; 2020 Jan; 38(3):644-654. PubMed ID: 31677948 [TBL] [Abstract][Full Text] [Related]
3. Oral Tecovirimat for the Treatment of Smallpox. Grosenbach DW; Honeychurch K; Rose EA; Chinsangaram J; Frimm A; Maiti B; Lovejoy C; Meara I; Long P; Hruby DE N Engl J Med; 2018 Jul; 379(1):44-53. PubMed ID: 29972742 [TBL] [Abstract][Full Text] [Related]
4. Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection. Duraffour S; Andrei G; Snoeck R IDrugs; 2010 Mar; 13(3):181-91. PubMed ID: 20191435 [TBL] [Abstract][Full Text] [Related]
5. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Russo AT; Grosenbach DW; Chinsangaram J; Honeychurch KM; Long PG; Lovejoy C; Maiti B; Meara I; Hruby DE Expert Rev Anti Infect Ther; 2021 Mar; 19(3):331-344. PubMed ID: 32882158 [TBL] [Abstract][Full Text] [Related]
6. Tecovirimat: First Global Approval. Hoy SM Drugs; 2018 Sep; 78(13):1377-1382. PubMed ID: 30120738 [TBL] [Abstract][Full Text] [Related]
7. The development and approval of tecoviromat (TPOXX Merchlinsky M; Albright A; Olson V; Schiltz H; Merkeley T; Hughes C; Petersen B; Challberg M Antiviral Res; 2019 Aug; 168():168-174. PubMed ID: 31181284 [TBL] [Abstract][Full Text] [Related]
9. Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection. Berhanu A; Prigge JT; Silvera PM; Honeychurch KM; Hruby DE; Grosenbach DW Antimicrob Agents Chemother; 2015 Jul; 59(7):4296-300. PubMed ID: 25896687 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model. Hutson CL; Kondas AV; Mauldin MR; Doty JB; Grossi IM; Morgan CN; Ostergaard SD; Hughes CM; Nakazawa Y; Kling C; Martin BE; Ellison JA; Carroll DS; Gallardo-Romero NF; Olson VA mSphere; 2021 Feb; 6(1):. PubMed ID: 33536322 [TBL] [Abstract][Full Text] [Related]
11. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Huggins J; Goff A; Hensley L; Mucker E; Shamblin J; Wlazlowski C; Johnson W; Chapman J; Larsen T; Twenhafel N; Karem K; Damon IK; Byrd CM; Bolken TC; Jordan R; Hruby D Antimicrob Agents Chemother; 2009 Jun; 53(6):2620-5. PubMed ID: 19349521 [TBL] [Abstract][Full Text] [Related]
12. Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus. Smith SK; Self J; Weiss S; Carroll D; Braden Z; Regnery RL; Davidson W; Jordan R; Hruby DE; Damon IK J Virol; 2011 Sep; 85(17):9176-87. PubMed ID: 21697474 [TBL] [Abstract][Full Text] [Related]
13. New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus. DeLaurentis CE; Kiser J; Zucker J Antimicrob Agents Chemother; 2022 Dec; 66(12):e0122622. PubMed ID: 36374026 [TBL] [Abstract][Full Text] [Related]
14. [We should be prepared to smallpox re-emergence.]. Shchelkunov SN; Shchelkunova GA Vopr Virusol; 2019; 64(5):206-214. PubMed ID: 32167685 [TBL] [Abstract][Full Text] [Related]
15. Molecule of the month. Tecovirimat. Drug News Perspect; 2008 Nov; 21(9):517. PubMed ID: 19180269 [No Abstract] [Full Text] [Related]
16. Effects of Treatment Delay on Efficacy of Tecovirimat Following Lethal Aerosol Monkeypox Virus Challenge in Cynomolgus Macaques. Russo AT; Grosenbach DW; Brasel TL; Baker RO; Cawthon AG; Reynolds E; Bailey T; Kuehl PJ; Sugita V; Agans K; Hruby DE J Infect Dis; 2018 Sep; 218(9):1490-1499. PubMed ID: 29982575 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Grosenbach DW; Berhanu A; King DS; Mosier S; Jones KF; Jordan RA; Bolken TC; Hruby DE Proc Natl Acad Sci U S A; 2010 Jan; 107(2):838-43. PubMed ID: 20080762 [TBL] [Abstract][Full Text] [Related]
18. A Glance at the Development and Patent Literature of Tecovirimat: The First-in-Class Therapy for Emerging Monkeypox Outbreak. Almehmadi M; Allahyani M; Alsaiari AA; Alshammari MK; Alharbi AS; Hussain KH; Alsubaihi LI; Kamal M; Alotaibi SS; Alotaibi AN; Aldhafeeri AA; Imran M Viruses; 2022 Aug; 14(9):. PubMed ID: 36146675 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans. Leeds JM; Fenneteau F; Gosselin NH; Mouksassi MS; Kassir N; Marier JF; Chen Y; Grosenbach D; Frimm AE; Honeychurch KM; Chinsangaram J; Tyavanagimatt SR; Hruby DE; Jordan R Antimicrob Agents Chemother; 2013 Mar; 57(3):1136-43. PubMed ID: 23254433 [TBL] [Abstract][Full Text] [Related]
20. Smallpox lesion characterization in placebo-treated and tecovirimat-treated macaques using traditional and novel methods. Bell TM; Facemire P; Bearss JJ; Raymond JL; Chapman J; Zeng X; Shamblin JD; Williams JA; Grosenbach DW; Hruby DE; Damon IK; Goff AJ; Mucker EM PLoS Pathog; 2024 Feb; 20(2):e1012007. PubMed ID: 38386661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]